EVO (Evotec SE) Operating Margin %: -29.64% (As of Mar. 2026)


EVO Evotec SE EVO
64 GF Score
Price $2.74
GF Value $4.27
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE Operating Margin %?

Evotec SE EVO +1.11% 64 Operating Margin % is -29.64% as of Mar. 2026. GuruFocus rates EVO with a GF Score™ of 64/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Evotec SE ranks worse than 80% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Evotec SE's Operating Income for the three months ended in Mar. 2026 was $-53.7 Mil. Evotec SE's Revenue for the three months ended in Mar. 2026 was $181.1 Mil. Therefore, Evotec SE's Operating Margin % for the quarter that ended in Mar. 2026 was -29.64%.

The historical rank and industry rank for Evotec SE's Operating Margin % or its related term are showing as below:

EVO' s Operating Margin % Range Over the Past 10 Years
Min: -11.06   Med: 8.54   Max: 22.34
Current: -11.06


EVO's Operating Margin % is ranked worse than
80% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs EVO: -11.06

Evotec SE's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Evotec SE's Operating Income for the three months ended in Mar. 2026 was $-53.7 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-95.4 Mil.


Evotec SE  (NAS:EVO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Evotec SE Operating Margin % Related Terms


Evotec SE Operating Margin % Historical Data

* Premium members only.

The historical data trend for Evotec SE's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Operating Margin % Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.74 2.77 -3.41 -9.90 -7.08

Evotec SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.91 -16.70 -27.22 14.69 -29.64

EVO vs ZTS, UTHR, VTRS: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Evotec SE's Operating Margin % falls into.


EVO
64GF Score
Evotec SE EVO
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Evotec SE's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-65.361 / 923.153
=-7.08 %

Evotec SE's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-53.668 / 181.091
=-29.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -29.64% mean?
Evotec SE (EVO) has a Operating Margin % of -29.64% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #764 out of 955 companies in the Drug Manufacturers industry, placing it in the top 80%.
Is Evotec SE's Operating Margin % too high?
Evotec SE's current Operating Margin % is -29.64%. Based on the distribution chart, Evotec SE ranks #764 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #764 out of 955 companies for Operating Margin %. This places Evotec SE in the lower half of its industry. The industry median Operating Margin % is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Operating Margin % is -29.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $2.74 — trading 35.8% below its estimated fair value. The current Operating Margin % is -29.64%. Evotec SE's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Evotec SE (EVO), the current Operating Margin % is -29.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (EVO) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of $2.74 is trading 35.8% below its estimated GF Value™ of $4.27. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for EVO:

  • Operating Margin %: -29.64%
  • GF Value™: $4.27 vs. price of $2.74 (35.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score

Get the complete analysis for EVO

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price
$4.27
GF Value